Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2013

01-06-2013 | Erratum

Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Authors: F. J. Afonso, U. Anido, O. Fernández-Calvo, S. Vázquez-Estévez, L. León, M. Lázaro, M. Ramos, L. Antón-Aparicio

Published in: Clinical and Translational Oncology | Issue 6/2013

Login to get access

Excerpt

Unfortunately, the original publication contains two errors. …
Metadata
Title
Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor
Authors
F. J. Afonso
U. Anido
O. Fernández-Calvo
S. Vázquez-Estévez
L. León
M. Lázaro
M. Ramos
L. Antón-Aparicio
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1032-2

Other articles of this Issue 6/2013

Clinical and Translational Oncology 6/2013 Go to the issue

Research Article

Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes

Research Article

Pilot study of feasibility and dosimetric comparison of prone versus supine breast radiotherapy

Educational Series – Red Series

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Research Article

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients

Research Article

Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer

Educational Series – Blue Series

Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits